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ABSTRACT 
Background: Heart failure guidelines recommend up-titration of ACE-inhibitors/ARBs, beta-
blockers and MRA’s to doses used in randomized clinical trials, but these recommended doses 
are often not reached. Up-titration might however not be necessary in all patients. We aimed to 
establish the role of blood biomarkers to determine which patients should or should not be up-
titrated.  
Methods: Clinical outcomes of 2516 patients with worsening heart failure from BIOSTAT-CHF 
were compared between 3 theoretical treatment scenarios: A) all patients are up-titrated to >50% 
of recommended doses; B) patients are up-titrated according to a biomarker-based treatment-
selection model; C) no patient is up-titrated to >50% of recommended doses. We conducted 
multivariable Cox regression using 161 biomarkers and their interaction with treatment, 
weighted for treatment-indication bias to estimate the expected number of deaths and/or heart-
failure hospitalizations at 24 months for all three scenarios. 
Results: Estimated death/hospitalization rates in 1802 patients with available (bio)markers were 
16%, 16%, and 26% respectively in ACE-inhibitor/ARB up-titration scenario A, B and C. 
Similar rates for beta-blocker and MRA up-titration scenarios A, B, and C were 23%, 19%, and 
24%, and 12%, 11% and 24 %, respectively. If up-titration was successful in all patients, an 
estimated 9.8, 1.3 and 12.3 events per 100 treated patients could be prevented at 24 months by 
ACE-inhibitor/ARB, beta-blocker and MRA therapy. Similar numbers were 9.9, 4.7 and 13.1 if 
up-titration treatment decision was based on a biomarker-based treatment-selection model. 
Conclusion: Up-titrating patients with heart failure based on biomarker values might have 
resulted in fewer deaths and/or hospitalizations compared to a hypothetical scenario in which all 
patients were successfully up-titrated. 
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Abbreviations:  
ACE-inhibitors: Angiotensin-converting-enzyme inhibitors 
ARB: Angiotensin Receptor Blocker 
AF: Atrial fibrillation 
BMI: Body mass index 
BNP: Brain natriuretic peptide 
BUN: Blood urea nitrogen 
DBP: Diastolic blood pressure 
CRP: C-reactive protein 
CRT: Cardiac resynchronization therapy 
ESC: European Society of Cardiology 
FGF23: Fibroblast Growth Factor 23 
GFR: Glomerular filtration rate 
HDL: High-density lipoprotein 
HF: Heart failure 
HFrEF: Heart failure with reduced ejection fraction 
ICD: Implantable cardioverter-defibrillator 
IGFBP-2: Insulin-like growth factor binding protein-2 
IQR: Interquartile range 
LDL: Low-density lipoprotein 
LVEF: Left ventricular ejection fraction 
MRA: MBNP: N-terminal prohormone of BNP 
NYHA: New York Heart Association 
SD: Standard deviation 
 
Condensed Abstract: Heart-failure guidelines recommend up-titration of ACE-inhibitors/ARBs, 
beta-blockers and MRA to doses used in RCTs. These doses are often not reached, and might not 
benefit all patients. We determined the probability of mortality and/or heart-failure 
hospitalization based on a biomarker-profile using 3 theoretical treatment scenarios: A) all 
patients are up-titrated to >50% recommended doses; B) patients are up-titrated according to a 
biomarker-based treatment-selection model; C) no patient is up-titrated to >50% recommended 
doses. Up-titrating patients with heart-failure based on biomarker values might have resulted in 
fewer deaths and/or hospitalizations compared to a scenario in which all patients were 
successfully up-titrated. 
  
Introduction 
Major improvements in pharmaceutical and device heart failure treatment of heart failure 
have been achieved in the past year. Evidence from large randomized clinical trials demonstrates 
that that angiotensin-converting-enzyme inhibitors (ACE-inhibitors), beta-blockers and 
mineralocorticoid receptor antagonists (MRAs) improve clinical outcome in patients with mild to 
moderate heart failure (1-8). In large randomized clinical trials, treatment doses were up-titrated 
to pre-specified doses, which have become the guideline-recommended doses. (9-12). Despite 
these improvements and recommendations, the prognosis of patients with heart failure remains 
poor (13-16), and in daily clinical practice the majority of patients do not achieve recommended 
doses (17-19). Although it is expected that most patients that achieve recommended doses will 
benefit from treatment, selected patients might not benefit from the recommended doses, but will 
experience side effects of ACE-inhibitors and beta-blocker treatment. A personalized medicine 
approach where patients who will not benefit from recommended ACE-inhibitor/ARB and beta-
blocker heart failure treatment might be selected by biomarkers, and might reduce the number of 
patients receiving treatment without benefit and improve overall outcome. 
In this in silico study, we used data from the BIOSTAT-CHF project to identify such 
treatment-selection markers. We hypothesized that biomarkers measured at baseline in 
serum/plasma of heart failure patients can identify whether patients benefit from recommended 
heart failure treatment or not. We developed models to estimate this benefit using 161 
established and novel biomarkers, including standard biochemical blood-parameters. We 
compared three theoretical treatment scenarios: A) all patients are up-titrated to >50% of 
recommended doses according to the ESC guidelines (9-11); B) patients will be up-titrated by a 
biomarker-based treatment-selection model; C) no patient is treated at >50% of recommended 
dose. 
Methods 
Patients 
BIOSTAT-CHF is a multicenter prospective study of 2516 patients from 69 centers in 11 
European countries (20). Included patients were aged >18 years with symptoms of new-onset or 
worsening heart failure, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% 
or B-type Natriuretic Peptide (BNP) and/or (N-terminal pro) B-type natriuretic peptide (NT-
proBNP) plasma levels >400 pg/ml or >2,000pg/ml, respectively. At inclusion, patients were 
treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of 
inclusion, and were not previously treated with evidence based therapies (ACE-inhibitor/ARB 
and beta-blocker) or were receiving ≤ 50% of the target doses of these drugs at the time of 
inclusion and had an anticipated initiation or up-titration of ACE-inhibitor/ARB and/or beta-
blocker therapy by the treating physician. IRB approval was obtained in all countries. 
Evidence-based heart failure treatment 
Patients were treated according to evidence based ESC heart failure guidelines available 
at time of inclusion (9-11). These recommend up-titrating patients to recommended doses of 
ACE-inhibitors/ARBs and beta-blockers, unless not tolerated or contra-indicated (9-11). In 
BIOSTAT-CHF, sub-optimally treated patients were included, and physicians were encouraged 
to up-titrate patients to recommended treatment doses within 3 months after inclusion. 
We recently published data from BIOSTAT-CHF showing that up-titrating patients to at 
least 50% of recommended ACE-inhibitor/ARB and beta-blocker doses results in comparable 
survival and/or heart failure related hospitalization reduction compared with patients that reached 
≥100% of recommended doses (21). We therefore considered patients successfully up-titrated 
when >50% of recommended dose was achieved after 3 months of up-titration. Inversely, we 
defined non-responders as patients who did not achieve more that 50% recommended treatment 
dose. All analyses were separately performed for ACE-inhibitors/ARBs and beta-blockers. In 
addition to ACE-inhibitor/ARB and beta-blocker treatment, we also looked at MRA guideline 
recommended treatment. Here we defined successful treatment as patients who achieved ≥50% 
of recommended treatment, and non-responding patient when <50% of recommended treatment 
dose was achieved. MRA treatment data was available at 9 months after inclusion. 
Disease outcome 
Median follow-up of the BIOSTAT-CHF project was 21 months with an interquartile 
range of 15-27 months. Primary patient outcome in BIOSTAT-CHF was the first occurrence of 
all-cause mortality or heart failure related hospitalization. Survival time was calculated from date 
of inclusion in BIOSTAT-CHF to date of death/heart failure hospitalization or date of censoring. 
Only patients who were at least followed for 3 months, were included in the present analysis. 
Biomarkers 
A total of 161 biomarkers were considered as treatment-selection markers. All markers 
were measured at inclusion of the patients. This included standard biochemical blood-parameters 
(hemoglobin, hematocrit, sodium, total cholesterol, HDL-cholesterol, LDL-cholesterol, glucose, 
serum creatinine, blood urea nitrogen (BUN), bilirubin, serum iron, potassium), heart failure 
markers (LVEF, NT-proBNP and BNP), 29 markers from the Luminex multiplexed bead-based 
immunoassay (Alere, San Diego, CA) heart failure panel (22, 23), and 92 peptide markers from a 
high-throughput technique using the Olink Proseek® Multiplex INF I96x96 kit, which measures 
92 selected inflammation-related proteins simultaneously in 1μl plasma samples. The kit uses a 
proximity extension assay (PEA) technology, where 92 oligonucleotide-labeled antibody probe 
pairs are allowed to bind to their respective target present in the sample. 
The 92 peptides measured by Olink® were normalized in arbitrary normalized protein 
expression units (NPX). Other biomarkers were normalized using Box-Cox transformations 
when deemed necessary. A complete list of all biomarkers and their summary statistics are 
shown in Online Table 1. 
Statistical analysis 
Imputation of missing data 
Patients in whom >50% or more biomarker values were missing were not included in the 
analyses. Remaining missing values were imputed using random forests regression models 
implemented in the mice package (24) of the R statistical program (version 3.2.4) (25). Five 
completed data sets were created. 
Indication bias 
Since BIOSTAT-CHF is not a randomized study, we adjusted for treatment indication-
bias. All analyses of the effect of successful up-titration treatment on mortality and/or 
hospitalization risk were inversely weighted with the probability of the given treatment. Given 
treatment is defined here as a successful up-titration to >50% of ESC recommended doses for 
ACE-inhibitor/ARB or beta-blocker or not or ≥50% ESC recommended MRA treatment dose. 
The probability of given treatment for a specific patient was modelled using a logistic regression 
model. All biomarkers were considered as predictor variables for successful up-titration. In 
addition, we considered 39 demographic and clinical predictor variables for prediction of the 
successful outcome of the up-titration (age, sex, race, BMI, blood pressure, heart rate, smoking, 
alcohol use, heart failure aetiology, heart failure duration, NYHA class, and several heart failure 
symptoms and comorbid conditions). We used lasso penalization to obtain sparse logistic models 
consisting of a limited number of predictor variables. Optimal penalty parameters were obtained 
by 10-fold cross-validation. Analyses were performed for each imputed dataset and the 
calculated treatment probabilities were averaged per patient over the five imputed datasets. 
Performance of the logistic models was quantified using optimism-corrected c-statistics using 
100 bootstrap samples, averaged over the imputed datasets.  
Death and/or heart failure hospitalization and treatment-biomarker interaction 
Mortality and/or heart failure hospitalization risk was modelled using the Cox regression 
model with given treatment as a stratum-variable. Therefore, we did not assume proportional 
hazards for the effect of treatment on mortality/hospitalization risk. The assumed proportional 
hazards assumption of the biomarkers was checked using Grambsch and Therneau's test 
implemented in the cox.zph function of the R statistical program (26). 
We performed multivariable Cox regression with all 161 biomarkers. We used the split 
sample technique to obtain a training sample consisting of 80% of the patients in the original 
index cohort and the remaining 20% of the patients formed the test sample. The split-sample 
procedure was repeated 100 times. In all 100 training samples, we used lasso penalization to 
obtain sparse Cox regression models consisting of a limited number of the 161 biomarkers. 
Optimal penalty parameters were obtained by 10-fold cross-validation. 
We performed separate analyses for patients who were successfully up-titrated to >50% 
of recommended treatment dose for either ACE-inhibitors/ARB’s or beta-blockers and for 
patients who were non-responders as defined by lack of up-titration (≤50% of recommended 
treatment dose). This resulted in 6 different models predicting mortality and/or heart failure 
hospitalization; three models predicting mortality and/or heart failure hospitalization in 
successfully up-titrated patients for ACE-inhibitors/ARB’s, beta-blockers and MRA’s, and three 
for non-responding patients who were up-titrated to ≤50% of recommended ACE-inhibitor/ARB 
and beta-blocker doses and <50% recommended MRA dose. We stratified on given treatment 
and considered both the main effects of all biomarkers as well as all interactions of biomarkers 
with treatment. In the 100 test samples, we subsequently evaluated the goodness of fit of the 
selected sparse Cox regression models. We calculated both calibration and discrimination 
statistics (c-statistic and shrinkage statistic). Moreover, the benefit of successful and not 
successful up-titration was calculated for the patients in the test samples. All analyses were 
inversely weighted with the probability of the given treatment to account for indication bias. 
Treatment benefit statistics 
We calculated the expected number of events at 24 months follow-up for three scenarios: 
A) if all patients are successfully up-titrated to >50% of recommended doses according to the 
ESC guidelines (≥50% for MRA’s); B) if all patients are up-titrated following a treatment-
strategy based on the biomarker values; C) if no patient is treated at >50% of recommended 
doses according to the ESC heart failure guidelines (≥50% for MRA’s). We performed all 
analyses for ACE-inhibitor/ARB and beta-blocker separately. For scenario B; we decided to up-
titrate when the probability of survival for mortality and/or hospitalization at 24 months for up-
titrating were higher than for not up-titrating, and vice versa. 
The survival probabilities were based on the difference of a patient's mean death and/or 
heart failure hospitalization probability at 24 months follow-up (𝑆(𝑡 = 24| … )) under both 
treatments according to the sparse Cox regression models estimated for the associated training 
sample:  
𝑆(𝑡 = 24|𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑢𝑝𝑡𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝑋 = 𝑥) − 𝑆(𝑡 = 24|𝑢𝑛𝑠𝑢𝑐𝑐𝑒𝑠𝑠𝑓𝑢𝑙 𝑢𝑝𝑡𝑖𝑡𝑟𝑎𝑡𝑖𝑜𝑛, 𝑋 = 𝑥). 
where 'X=x' represent specific levels of the biomarkers selected in the Cox models for predicting 
mortality and/or heart failure hospitalization in the successfully and not-successfully up-titrated 
patients, respectively. The difference was averaged over all test samples that included the 
specific patient, and was subsequently multiplied with total number of patients. This benefit-
statistic can be interpreted as the number of deaths and/or heart failure hospitalizations that is 
prevented at 24 months by successful up-titrating to >50% of recommended doses according to 
the ESC guidelines. 
Benefit-statistics were calculated for each test sample separately. The standard deviation 
of the benefit-statistics over the 100 test samples was then used as an estimate of the standard 
error of the mean benefit-statistic. 
Results 
Of the 2516 patients included in the index cohort, 151 patients died, 23 patients were 
censored before 3 months follow-up and 242 patients had a LVEF >40%; these patients were 
excluded from the current data-analysis. Of the remaining 2100 patients, there were 298 patients 
with missing values on more than 50% of the biomarkers. Subsequent analyses were done with 
data from the remaining 1802 patients. Because BIOSTAT-CHF is not a randomized trial, we 
corrected for the probability of being up-titrated to >50% of recommended treatment dose. 
Biomarkers predictive for up-titration and subsequent indication-bias correction is presented in 
supplementary data. Of the 1802 patients, 529 (29%) were up-titrated to >50% of recommended 
ACE-inhibitor/ARB dose and 318 (18%) to >50% of recommended beta-blocker dose. We have 
MRA treatment data for 1423 patients at 9 months after inclusion. Of these 1423 patients, 14% 
(195) patients were successfully up-titrated to ≥50% recommended treatment doses (2% (28) to 
>50% recommended doses). Patient characteristics of patients achieving >50 recommended 
ACE-inhibitor/ARB and beta-blocker dose and ≥50% recommended MRA dose and of those 
who did not respond to recommended treatment are presented in Table 1. 
Multivariable treatment-selection markers 
To distinguish patients who benefited from up-titration from those who did not, we 
created two models. From 161 biomarkers, we first identified the strongest biomarkers to predict 
clinical events (death of heart failure hospitalization) despite successful up-titration with either 
ACE-inhibitors/ARBs or beta-blockers. Most frequently selected biomarkers are reported in 
Online Table 2. BUN, FGF23 and pro-ENK were the strongest predictors of clinical events in 
patients that were successfully up-titrated with ACE-inhibitors/ARBs. Serum creatinine, galetin-
3, ST2 and albumin were the strongest predictors of clinical events in patients that were 
successfully up-titrated with beta-blockers (Online Table 3). Predictive biomarkers for events in 
up-titrated patients with MRAs are presented in Online Table 4. 
In the second model, we identified the strongest biomarkers to predict clinical events in 
patients who were NOT successfully up-titrated with either ACE-inhibitors/ARBs or beta-
blockers. FGF23, BUN, cystatin C, ST2, WAP-4C and IGFBP-2 were the strongest predictors of 
clinical events in patients that were NOT successfully up-titrated with ACE-inhibitors/ARBs. 
FGF23, cystatin C, BUN, WAP4C and NT-proBNP were the strongest predictors of clinical 
events in patients that were NOT successfully up-titrated with beta-blockers. 
The treatment-selection models had reasonable performances for the patients in the test 
sets. Averaged c-statistics for ACE-inhibitor/ARB models were 0.74 (0.68-0.80) in up-titrated 
patients, and 0.77 (95% CI 0.70-0.83) in not-up-titrated patients, respectively. Beta-blocker 
treatment-selection models averaged c-statistics were 0.75 (95% CI 0.70-0.82) in up-titrated 
patients, and 0.78 (95% CI 0.73-0.83) in not-up-titrated patients, respectively. C-statistic for 
MRA treatment-selection models were 0.65 (95% CI 0.56-0.74) and 0.77 (0.71-0.86) in up-
titrated and NOT up-titrated patients. 
Using both models, we were able to calculate survival probability at 24 months for both 
scenarios (successful or non-successful up-titration). The scenario with the highest probability 
was considered the most beneficial one for the individual patient. In 2% (n=42) of patients, the 
highest probability was found in patients who were not successfully up-titrated with ACE-
inhibitors/ARBs. Patients characteristics of these patients are presented in Table 3. Patients not 
benefitting from ACE-inhibitor/ARB up-titration were younger, more frequent smokers, with 
less AF; higher haemoglobin and BUN, but lower heart rate and NT-proBNP levels. In 33% 
(n=592) of patients, the highest survival probability was found in patients who were not 
successfully up-titrated with beta-blockers. Patients characteristics of these patients are presented 
in Table 3. Patients not benefitting from beta-blocker up-titration were older, leaner, more 
frequently smoker or former smoker. The also had less ischemic HF, but more myocardial 
infarction, and other co-morbidities. They also had significantly higher LVEF, (NT-pro)BNP, 
BUN and creatinine, levels, and lower DBP, heart rate, haemoglobin and eGFR levels. Patients 
for whom up-titrating MRA treatment was not beneficial for 13% (n=184) of the patients. 
Clinical events according to the three hypothetical scenarios 
Kaplan-Meier curves for ACE-inhibitor/ARB scenarios are presented in Figure 1. 
Mortality and/or heart failure hospitalization was highest in the scenario where no patient was 
up-titrated to at least 50% of the recommended dose. Patients who were up-titrated based on their 
biomarker profile had the lowest risk of death and/or heart failure hospitalization.  
Estimated event rate and averaged expected events at 24 months for each of the three 
hypothetical scenarios are presented in Table 2. If all patients were successfully up-titrated to 
>50% of recommended doses ACE-inhibitor/ARBs (Scenario A), estimated death and/or hospital 
admission occurred in 297 (260-335) patients. If patients were up-titrated with ACE-
inhibitor/ARBs following a treatment-strategy based on the biomarker values (Scenario B), 
estimated death and/or hospital admission occurred in 296 (260-333) patients. If no patient was 
treated with >50% of recommended doses ACE-inhibitor/ARBs (Scenario C), estimated death 
and/or hospital admission occurred in 474 (438-511) patients. Up-titrating ACE-inhibitor/ARBs 
to >50% of recommended dose compared to 50% less than recommended dose resulted in 174 
fewer events (95% CI 128-227) ; p-value= 0.0003). Per 100 treated patients, this means that 9.8 
(95% CI 7.1-12.6) fewer events were seen in this scenario. The biomarkers-based approach led 
to 178 fewer events (95% CI 130-226 ; p-value=0.0003) compared to the 50% recommended 
dose group. Per 100 treated patients this resulted in 9.9 (95% CI 7.2-12.6) fewer events. 
Kaplan-Meier curves for beta-blocker scenarios are presented in Figure 2. Mortality 
and/or heart failure hospitalization was highest in the scenario where no patient was up-titrated to 
at least 50% of the recommended dose. Patients who were up-titrated based on their biomarker 
profile had the lowest risk of death and/or heart failure hospitalization, which was slightly lower 
compared to a scenario in which all patients were up-titrated to >50% of the recommended dose 
of ACE-inhibitor/ARBs. 
Estimated event rate and averaged expected events at 24 months for each of the three 
hypothetical scenarios are presented in Table 2. If all patients were successfully up-titrated to 
recommended beta-blocker doses (Scenario A), estimated death and/or hospital admission 
occurred in 404 (95% CI 332-477) patients. If patients were up-titrated with beta-blockers 
following a treatment-strategy based on the biomarker values (Scenario B), estimated death 
and/or hospital admission occurred in 345 (95% CI 300-389) patients. If no patient was treated 
with recommended doses beta-blockers (Scenario C), estimated death and/or hospital admission 
occurred in 428 (95% CI 391-466) patients. Up-titrating beta-blockers to >50% of recommended 
dose compared to ≤50% resulted in 24 less events (95% CI -54-103); p-value=0.50). The 
biomarkers-based approach led to 84 fewer events (95% CI 40-128; p-value=0.01) compared to 
the ≤50% recommended dose group. This means that 1.3 (95% CI -3-5.7) and 4.7 (95% CI  2.2-
7.1) events could be prevented per 100 treated patients in both scenarios. 
When considering up-titrating to both 50% of recommended ACE-inhibitor/ARB and 
beta-blocker dose we estimated that 222 (95% CI 147-298) event could be prevented when all 
patients would be up-titrated to at least 50% recommended treatment dose for both ACE-
inhibitors/ARBs and beta-blockers. Another 14 events (95% CI -52-80) could be prevented when 
the decision to up-titrated was based on a biomarker-based model (Online Appendix). 
For MRA treatment we estimated that not up-titrating patients to ≥50% of recommended 
MRA dose would result in 437 (95% CI 405-469) events. When we would up-titrate all patients 
this would be reduced with 222 (95% CI 147-298; p=0.0001) events to 215 (95% CI 150-280). 
Our biomarker-based model resulted in 236 (95% CI 170-303; p=0.0004) less events than when 
no patient would be up-titrated to ≥50% of recommended MRA dose. 
Discussion 
We hypothesized that not every patient with HFrEF will benefit from maximal up-
titration with either ACE-inhibitors/ARBs or beta-blockers. We therefore tested 3 hypothetical 
scenarios: A) all patients were up-titrated to >50% of recommended ACE-inhibitor/ARB or beta-
blocker dose, B) all patients were up-titrated or not based on a biomarker model, and C) no 
patient was up-titrated to >50% of recommended ACE-inhibitor/ARB or beta-blocker dose. Our 
models estimated that the highest number of events would have occurred in Scenario C) and the 
lowest number of events in Scenario B). The present results from this novel approach suggest 
that some patients do not benefit from maximally recommended doses. 
There are many biomarkers known to influence therapeutic response and survival 
(27,28), and there have been many attempts to use biomarker levels for evaluating treatment 
response and outcome (29). However, no models were developed using a multitude of 
biomarkers to estimate and compare the risk of mortality and/or heart failure hospitalization in 
up-titrated and not up-titrated patients. 
We recently published a meta-analysis on all prognostic heart failure models and an 
average c-statistics for predicting mortality and/or heart failure related hospitalization of 0.68 
(30). Thus, the biomarker-based treatment-selection models in the present paper have similar 
predictive performance compared to existing models. Most of these prognostic models were 
based on clinical and biographical patient-characteristics with few biomarkers. The association 
of some biomarkers that we identified (e.g. NT-proBNP, BUN, ST2, and hemoglobin) with 
mortality or heart failure hospitalization-risk in heart failure patients is well known (9, 10, 31-
38), but a differential predictive value in patients who were successfully up-titrated versus those 
who were not, was as yet unknown. This observation may be useful to identify residual heart 
failure disease and additional treatment targets in heart failure patients. Although our biomarker-
based treatment-selection models have comparable performance to other prediction models, the 
performance of these models is still modest and they have large confidence bounds. In this study, 
we only looked at benefit, and did not take harm into account. Not up-titrating might be more 
beneficial for a patient, however up-titrating might not do harm. 
We decided to dichotomize up-titration into successful or not. In clinical practice, the 
actual doses of ACE inhibitors/ARB’s and beta-blockers vary substantially. Since we recently 
published data from BIOSTAT-CHF showing that up-titrating patients to 50-99% of 
recommended ACE-inhibitor/ARB and beta-blocker doses results in comparable survival and/or 
heart failure related hospitalization reduction (21), we considered patients successfully up-
titrated when >50% of recommended dose was achieved after 3 months of up-titration. 
The BIOSTAT-CHF population mainly consists of patients with advanced heart failure 
who may be more likely to have limited benefit from up-titration of ACE-inhibitor/ARB and 
beta-blocker therapy. These patients may be worsened by even small doses of beta-blockers, or 
they may experience excessive hypotension and worsening renal function from ACE-
inhibitor/ARBs. BIOSTAT-CHF was specifically designed to record reasons for not up-titrating 
to recommended treatment doses. Only in 26 and 22% of the patients for ACE-inhibitors/ARBs 
and beta-blockers, this was caused by intolerance to the drug, either because of organ 
dysfunction. In the majority of patients, no specific reason was provided (21). This analysis 
supports the concept that even less clinical ill patients may not be helped by ACE-inhibitor/ARB 
and beta-blocker up-titration. 
There were significant hemodynamic differences (heart rate and blood pressure) between 
patients who were up-titrated >50% of recommended treatment dose and those who were not. 
This might suggest that these and other variables were at least partly responsible for the different 
achieved up-titration doses. We corrected for these difference by propensity score matching and 
inverse probability of treatment weighing. 
Limitations 
One major important limitation of the present study is that heart failure treatment was not 
randomly assigned in our study. Up-titration of ACE inhibitor/ARB’s and beta-blockers has been 
shown to be beneficial on average in many randomized clinical trials and has been adopted into 
the ESC heart failure guidelines. It is striking, however, that in clinical practice so many patients 
are not up-titrated to >50% of recommended dose. We tried to adjust for this treatment-
indication bias, introduced in this cohort type BIOSTAT-CHF study, by two generally accepted 
advanced statistical methods: propensity scoring and inverse probability of treatment weighing. 
Whether this corrected the treatment-indication bias sufficiently is unfortunately not testable. 
A second limitation is the large number of biomarkers that we analysed which increased 
the chance of false positive findings. We used Bonferroni correction of p-values and we used 
sparse regression models to minimize the risk of overfitting. Lasso penalization is known to yield 
too large regression models (with too many predictor variables) (39), so our models might still be 
somewhat larger than necessary (on average > 23 biomarkers). We used a repeated split-sample 
technique to cross-validate benefit- and fit-statistics to reduce the effect of overfitting. 
A third limitation of our analyses is that we ignored patients who died in the first three 
months of up-titration period. We excluded 151 deaths and the survival at three months was only 
93%. We made a prediction model for the risk of death within 3 months and found that FGF23, 
NT-proBNP, BNP, low haemoglobin, TNI, ET1, ST2, WAP4C and CRP were the most 
important predictors of death within 3 months. This selection of biomarkers coincided largely 
with the set of biomarkers that we identified as prognostic in the patients who were not 
successfully up-titrated for both ACE-inhibitors/ARBs and beta-blockers. Therefore, we assume 
that the presented results were not largely biased by the removal of the 151 deaths. We only had 
MRA dose data available after 9 months follow-up. This introduces additional bias because 
excluded even more patients than for the ACE-inhibitor/ARB and beta-blockers analyses. We 
tried to correct for this by inverse probability weighting. Although, we cannot test if this was 
sufficient, we think the MRA data adds important information to our models. 
Because not all biomarkers used in our treatment-selection models were measured in the 
validation cohort of BIOSTAT-CHF existing of 1728 patients, we unfortunately could not 
validate our results in this cohort. In the future, and when funding is available we aim to measure 
the missing biomarkers and validate our treatment-selection models in this cohort as well. 
We found substantial differences between patients of which the model assumed not to 
benefit from ACE-inhibitor/ARB up-titration and patients of which the model assumed not to 
benefit from beta-blocker up-titration. Patients not benefitting from ACE-inhibitor/ARB up-
titration were younger, with lower BNP and NT-proBNP, higher haemoglobin levels. Patients 
not benefitting from beta-blocker up-titration, conversely, were more often older, had higher 
BNP and NT-proBNP, lower haemoglobin compared to patients benefitting from beta-blocker 
up-titration. Blood urea nitrogen was elevated and heart rate was lower in both patients not 
benefitting from ACE-inhibitor/ARB up-titration and patients not benefitting from beta-blocker 
up-titration. 
Other possible limitations that could not be addressed in our cohort are the fact that our 
data is unfortunately limited to Caucasian patients only, and that there was a very low use of 
device therapy. This would possibly limit the use of our biomarker-selection model in a more 
heterogeneous population. The percentage of device therapy is nevertheless comparable to 
EMPHASIS-HF which recruited patients at the same time as BIOSTAT-CHF (40). 
Biomarkers predictive for mortality and/or hospitalization, were also markedly different 
between patients who were successfully up-titrated or not. This might have been expected 
because biomarkers related to ACE inhibition/ARB and beta-blocking pathways are likely to 
change substantially as a result of up-titration (41). 
Conclusion 
A biomarker-based treatment up-titration choice in patients with heart failure was 
favourable over both a hypothetical scenario in which all patients would have been successfully 
up-titrated to >50% of recommended of ACE-inhibitor/ARB and beta-blocker dose and ≥50% 
MRA dose. We estimated that 1 in 50, 1/3 and 1/8 patients will not benefit from ACE- 
inhibitor/ARB, beta-blocker or MRA up-titration, but their mortality/hospitalization hazards do 
not increase much by up-titration. Because of the nature of this study, and the small differences 
between biomarker-based treatment choice and the scenario in which all patients would have 
been successfully up-titrated, we suggest that up-titration should always be attempted in heart 
failure patients, which should lead to improved treatment of life-saving therapies across Europe. 
  
PERSPECTIVES 
Competency in Medical Knowledge: Not all patients benefit from up-titrating ACE-
inhibitor/ARB, beta-blocker and MRA to high evidence based recommended treatment dose. 
Predicting benefit based on treatment-selection models using individual biomarker profiles 
results in a higher reduction of mortality and/or heart failure related hospitalization than when all 
patients are up-titrated, although the difference is small. 
Competency in Patient Care: A patient should be up-titrated to evidence based recommended 
treatment dose or not based on a biomarker profile using our treatment-selection models. This 
reduces the change of death and/or heart failure related hospitalization. 
Translational Outlook: We have developed treatment-selection models in which patients 
should be up-titrated or not based on biomarker profiles. These biomarker treatment-selection 
models should be tested in a randomized fashion. The biomarkers selected in our treatment-
selection models might lead to more insight into heart failure pathogenesis, and may lead to new 
treatment options. 
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Figure Legends 
Central Illustration: Biomarker Guided treatment in heart failure. A multitude of biomarker 
values determine if a patient should be treated to evidence based recommended treatment or not. 
Figure 1. Estimated Kaplan-Meier survival curves based on three scenarios for up-titrating 
ACE-inhibitors/ARBs. Estimated Kaplan-Meier survival curves with the expected event-free 
survival rate and time in months based on three scenarios (green, blue and red lines): A) if all 
patients were up-titrated to >50% of recommended ACE-inhibitor/ARB dose (green); B) if all 
patients were up-titrated according to biomarker-selection model (blue); C) if no patient was up-
titrated to >50% of recommended ACE-inhibitor/ARB dose (red), with 95% confidence interval.  
Figure 2. Estimated Kaplan-Meier survival curves based three scenarios for up-titrating 
beta-blockers. Estimated Kaplan-Meier survival curves with the expected event-free survival 
rate and time in months based on three scenarios (green, blue and red lines): A) if all patients 
were up-titrated to >50% of recommended beta-blocker dose (green); B) if all patients were up-
titrated according to biomarker-selection model (blue); C) if no patient was up-titrated to >50% 
of recommended of beta-blocker dose (red), with 95% confidence interval.  
Figure 3. Estimated Kaplan-Meier survival curves based three scenarios for up-titrating 
MRA’s. Estimated Kaplan-Meier survival curves with the expected event-free survival rate and 
time in months based on three scenarios (green, blue and red lines): A) if all patients were up-
titrated to ≥50% of recommended MRA dose (green); B) if all patients were up-titrated 
according to biomarker-selection model (blue); C) if no patient was up-titrated to ≥50% of 
recommended of MRA dose (red), with 95% confidence interval.  
 
 
Table 1: Baseline characteristics of the patients who were up-titrated to >50% of recommended ACE-inhibitor/ARB and beta-blocker 
and ≥50% MRA dose and those who were not. 
 ACE-inhibitor/ARB beta-blocker MRA 
  successful up-titration 
no 
successful 
up-titration P - value successful up-titration 
no 
successful 
up-titration P - value successful up-titration 
no 
successful 
up-titration P - value 
Number of patients: n (%) 529 1273   318 1484   195 1228   
% of recommended ACE-inhibotor/ARB dose: 
mean (SD) 100 (28) 29 (18)   61 (39) 48 (38)   54 (38) 52 (39)   
% of recommended beta-blocker dose: mean 
(SD) 45 (32) 34 (30)   93 (18) 25 (17)   38 (30) 37 (31)   
Age (years): mean (SD) 66.36 (11.85) 
68.15 
(12.12) 0.004 66.14 (12.63) 
67.94 
(11.92) 0.02 63.21 (12.35) 
67.71 
(11.89) <0.00001 
Male gender: n (%) 395 (75%) 967 (76%) 0.56 235 (74%) 1127 (76%) 0.44 161 (83%) 914 (74%) 0.01 
Caucasian ethnicity: n (%) 523 (99%) 1259 (99%) 0.29 314 (99%) 1468 (99%) 0.04 187 (96%) 1219 (99%) 0.0006 
BMI (kg/m2): mean (SD) 28.93 (6.02) 27.49 (5.26) <0.00001 28.41 (5.57) 27.81 (5.51) 0.09 28.84 (5.55) 27.87 (5.51) 0.02 
Systolic blood pressure: mean (SD) 130.04 (22.37) 
121.24 
(20.5) <0.00001 125.47 (21.7) 
123.46 
(21.37) 0.13 121.62 (18.39) 
125.68 
(21.24) 0.006 
Diastolic blood pressure (mmHg): mean (SD) 79.03 (13.71) 73.68 (12.6) <0.00001 78.35 (14.45) 
74.58 
(12.77) 0.00002 75.03 (11.24) 
76.36 
(13.35) 0.14 
Heart rate (bpm): mean (SD) 79.88 (20.33) 
79.97 
(19.19) 0.93 85.3 (22.25) 78.8 (18.7) <0.00001 80.66 (18.97) 
79.87 
(20.29) 0.59 
Smoking (current/ever/never): n 197/256/76 450/630/193 0.73 101/177/40 546/709/229 0.04 63/94/38 450/602/176 0.14 
Alcohol use: n (%) 368 (70%) 909 (71%) 0.45 203 (64%) 1074 (72%) 0.003 132 (68%) 872 (71%) 0.33 
Ischemic HF etiology: n (%) 261 (49%) 563 (44%) 0.05 163 (51%) 661 (45%) 0.03 100 (51%) 584 (48%) 0.33 
HF duration (years): median (IQR) 8.81 (4.43-14.09) 
7.59 (3.34-
13.2) 0.5 8.54 (3.77-17.02) 
7.64 (3.49-
12.72) 0.39 10.52 (5.86-15.42) 
6.76 (2.89-
12.93) 0.27 
NYHA class III/IV: n (%) 244 (46%) 509 (40%) 0.02 134 (42%) 619 (42%) 0.89 83 (43%) 566 (46%) 0.36 
LVEF: median (IQR) 29 (24-34) 28 (22-34) 0.0005 29 (24-34) 29 (24-34) 0.3 24 (19-29) 29 (24-34) 0.00001 
NT-proBNP, ng/L: median (IQR) 32109 (29824-34465) 
33454 
(30868-
35940) 0.00001 32593 (30378-35101) 
32919 
(30630-
35676) 0.19 32008 (29504-34411) 
32704 
(30398-
35513) 0.03 
Oedema, % (n) 228 (43%) 603 (47%) 0.1 156 (49%) 675 (45%) 0.25 86 (44%) 526 (43%) 0.74 
Orthopnoea, % (n) 150 (28%) 431 (34%) 0.02 82 (26%) 499 (34%) 0.006 62 (32%) 366 (30%) 0.58 
Rales >1/3 up lung fields, % (n) 44 (19%) 125 (19%) 0.98 17 (12%) 152 (20%) 0.03 12 (13%) 104 (18%) 0.21 
Jugular venous pressure, % (n) 111 (29%) 281 (31%) 0.45 63 (28%) 329 (31%) 0.37 43 (30%) 240 (27%) 0.43 
Hepatomegaly, % (n) 60 (11%) 184 (14%) 0.07 39 (12%) 205 (14%) 0.45 39 (20%) 125 (10%) 0.00007 
Hypertension, % (n) 349 (66%) 731 (57%) 0.0007 195 (61%) 885 (60%) 0.58 107 (55%) 750 (61%) 0.1 
Atrial fibrillation, % (n) 209 (40%) 564 (44%) 0.06 163 (51%) 610 (41%) 0.0009 80 (41%) 518 (42%) 0.76 
Myocardial infarction, % (n) 188 (36%) 491 (39%) 0.23 113 (36%) 566 (38%) 0.38 61 (31%) 441 (36%) 0.21 
PCI, % (n) 106 (20%) 285 (22%) 0.27 72 (23%) 319 (21%) 0.65 39 (20%) 260 (21%) 0.71 
CABG, % (n) 70 (13%) 220 (17%) 0.03 47 (15%) 243 (16%) 0.48 23 (12%) 183 (15%) 0.25 
None 427 (24%) 932 (52%) 0.02 234 (13%) 1125 (62%) 0.52 136 (10%) 969 (68%) 0.004 
Pacemaker only 28 (2%) 89 (5%)   16 (1%) 101 (6%)   8 (1%) 80 (6%)   
ICD only 31 (2%) 121 (7%)   30 (2%) 122 (7%)   25 (2%) 84 (6%)   
CRT only 11 (1%) 24 (1%)   7 (0%) 28 (2%)   5 (0%) 19 (1%)   
ICD and CRT 31 (2%) 102 (6%)   30 (2%) 103 (6%)   20 (1%) 72 (5%)   
Other 1 (0%) 5 (0%)   1 (0%) 5 (0%)   1 (0%) 4 (0%)   
Diabetes mellitus, % (n) 182 (34%) 389 (31%) 0.11 97 (31%) 474 (32%) 0.62 63 (32%) 351 (29%) 0.29 
COPD, % (n) 70 (13%) 220 (17%) 0.03 42 (13%) 248 (17%) 0.12 28 (14%) 185 (15%) 0.8 
Stroke, % (n) 40 (8%) 122 (10%) 0.17 20 (6%) 142 (10%) 0.06 12 (6%) 112 (9%) 0.17 
Peripheral artery disease, % (n) 46 (9%) 142 (11%) 0.12 27 (8%) 161 (11%) 0.21 16 (8%) 121 (10%) 0.47 
Aldosterone antagonists, % (n) 267 (50%) 719 (56%) 0.02 150 (47%) 836 (56%) 0.003 156 (80%) 621 (51%) <0.00001 
Loop diuretics, % (n) 526 (99%) 1268 (100%) 0.61 317 (100%) 1477 (100%) 0.7 194 (99%) 1221 (99%) 0.92 
Digoxin, % (n) 82 (16%) 242 (19%) 0.08 54 (17%) 270 (18%) 0.61 50 (26%) 206 (17%) 0.003 
Haemoglobin, g/dL: mean (SD) 12.69 (1.73) 12 (2) <0.00001 12.52 (1.81) 12 (2) 0.13 12.71 (1.79) 13 (2) 0.14 
Creatinine, Œºmol/L: median (IQR) 481 (470-500) 
491 (470-
515) <0.00001 484 (467-506) 
487 (467-
510) 0.19 482 (463-497) 
484 (463-
508) 0.09 
BUN, mmol/L: median (IQR) 25.5 (24.2-31.6) 29 (24-35) <0.00001 26.7 (23.5-32.4) 28 (23-34) 0.005 28 (22.7-32.5) 27 (23-33) 0.69 
GFR MDRD formula, mL/min.1.73m2: mean (SD) 71 (22) 64 (24) <0.00001 68 (24) 65 (23) 0.09 73 (20) 67 (23) 0.001 
Sodium, mmol/L: mean (SD) 138.85 (3.55) 
138.06 
(3.81) 0.00004 138.62 (3.46) 
138.22 
(3.81) 0.07 138.56 (3.84) 138.53 (3.6) 0.91 
Potassium, mmol/L: mean (SD) 3.24 (0.53) 3.29 (0.56) 0.07 3.24 (0.51) 3.28 (0.56) 0.2 3.19 (0.5) 3.28 (0.56) 0.01 
BNP, pg/mL: median (IQR) 3931 (3624-4227) 
4010 (3624-
4438) 0.04 3966 (3496-4482) 
3984 (3496-
4343) 0.92 3991 (3418-4172) 
3937 (3418-
4319) 0.84 
 BNP: brain natriuretic peptide; BUN: blood urea nitrogen; CRT: cardiac resynchronization therapy ; GFR: glomerular filtration rate; ICD: implantable cardioverter-defibrillator IQR: interquartile range; 
LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; N-terminal prohormone of BNP; SD: standard deviation 
Table 2: Estimation of mortality and/or heart failure hospitalizations at 24 months three 
scenarios: Scenario A) if all patients are successfully up-titrated to more than 50% of 
recommended dose; scenario B) if up-titration was based on the biomarker treatment-selection 
model; scenario C) if no patient was successfully up-titrated for ACE-inhibitors/ARB’s.  
 
ACE-inhibitor/ARB Scenario A Scenario B  Scenario C 
Estimated event rate at 24 months  16% 16% 26% 
Estimated number of events (95% CI) 297 (260-335) 296 (260-333) 474 (438-511) 
Estimated event reduction compared to scenario C (95% CI) 177 (128-227) 178 (130-226) - 
Estimated event reduction compared to scenario C (95% CI) per 
100 treated patients 
9.8 (7.1-12.6) 9.9 (7.2-12.6)  
 
Beta-blocker Scenario A Scenario B  Scenario C 
Estimated event rate at 24 months 23% 19% 24% 
Estimated number of events (95% CI) 404 (332-477) 345 (300-389) 428 (391-466) 
Estimated event reduction compared to scenario C (95% CI) 24 (-54-102.55) 84 (40-128) - 
Estimated event reduction compared to scenario C (95% CI) per 
100 treated patients 
1.3 (-3-5.7) 4.7 (2.2-7.1)  
 
MRA Scenario A Scenario B  Scenario C 
Estimated event rate at 24 months 12% 11% 24% 
Estimated number of events (95% CI) 215 (150-280) 201 (147-255) 437 (405-469) 
Estimated event reduction compared to scenario C (95% CI) 222 (147-298) 236 (170-303) - 
Estimated event reduction compared to scenario C (95% CI) per 
100 treated patients 
12.3 (8.1-16.5) 13.1 (9.4-16.8)  
Scenario A) if all patients are successfully up-titrated; scenario B) if up-titration was based on the biomarker treatment-selection model; scenario 
C) if no patient was successfully up-titrated; CI: confidence interval 
Table 3: Characteristics of patients who did benefit from ACE-inhibitor/ARB, beta-blocker or MRA up-titration and those who did 
not. 
 ACE-inhibitor/ARB beta-blocker MRA 
 benefit up-titration 
NOT benefit 
up-titration P-value 
benefit up-
titration 
NOT benefit 
up-titration P-value benefit up-titration 
NOT benefit up-
titration P-value 
Number of patients: n (%) 1760 42   1210 592   1573 229   
% of recommended ACE-inhibotor/ARB dose: mean 
(SD) 50 (39) 57 (41)   51 (38) 47 (40)   49 (39) 59 (39)   
% of recommended beta-blocker dose: mean (SD) 37 (31) 41 (32)   37 (31) 36 (32)   37 (32) 37 (28)   
Age (years): mean (SD) 67.72 (12) 63.37 (14) 0.05 65.93 (12.13) 71.08 (11.18) <0.00001 68.04 (12.04) 64.77 (11.88) 0.0001 
Male gender: n (%) 1331 (76%) 31 (74%) 0.79 922 (76%) 440 (74%) 0.38 1219 (77%) 143 (62%) <0.00001 
Caucasian ethnicity: n (%) 1742 (99%) 40 (95%) 0.08 1194 (99%) 588 (99%) 0.54 1555 (99%) 227 (99%) 0.42 
BMI (kg/m2): mean (SD) 27.89 (5.55) 28.82 (4.22) 0.18 28.37 (5.72) 26.99 (4.98) <0.00001 27.86 (5.55) 28.27 (5.39) 0.3 
Systolic blood pressure: mean (SD) 123.67 (21.46) 
129.81 
(19.94) 0.06 124.26 (21.77) 122.9 (20.73) 0.2 123.26 (21.44) 127.61 (21.09) 0.004 
Diastolic blood pressure (mmHg): mean (SD) 75.18 (13.15) 
78.07 
(13.62) 0.18 76.23 (13.53) 73.23 (12.13) <0.00001 74.87 (13.11) 77.8 (13.26) 0.002 
Heart rate (bpm): mean (SD) 80.05 (19.63) 
75.24 
(13.49) 0.03 80.91 (19.36) 77.97 (19.72) 0.003 80.62 (19.68) 75.29 (17.72) 0.00004 
Smoking (current/ever/never): n 626/866/268 21/20/1 0.03 417/584/209 230/302/60 0.0003 560/779/234 87/107/35 0.72 
Alcohol use: n (%) 1246 (71%) 31 (74%) 0.68 857 (71%) 420 (71%) 0.94 1094 (70%) 183 (80%) 0.0009 
Ischemic HF etiology: n (%) 801 (46%) 23 (55%) 0.23 582 (48%) 242 (41%) 0.004 715 (45%) 109 (48%) 0.54 
HF duration (years): median (IQR) 8.02 (3.55-13.4) 
3.54 (1.6-
6.59) 0.2 8.34 (3.78-13.54) 
6.38 (2.61-
12.46) 0.31 8.3 (3.27-13.74) 5.8 (5.03-8.84) 0.28 
NYHA class III/IV: n (%) 731 (42%) 22 (52%) 0.16 498 (41%) 255 (43%) 0.44 618 (39%) 135 (59%) <0.00001 
LVEF: median (IQR) 29 (24-34) 29 (24-34) 0.19 27 (23-34) 29 (24-34) 0.00001 28 (23-34) 29 (24-36) <0.00001 
NT-proBNP, ng/L: median (IQR) 32900 (30630-35620) 
27928 
(26980-
32965) 0.01 
32635 (30247-
35086) 
33593 (31140-
36655) 0.00003 
33143 (30708-
35788) 
31303 (29506-
33500) 0.00001 
Oedema, % (n) 818 (46%) 13 (31%) 0.05 558 (46%) 273 (46%) 1 753 (48%) 78 (34%) 0.00009 
Orthopnoea, % (n) 567 (32%) 14 (33%) 0.88 404 (33%) 177 (30%) 0.14 538 (34%) 43 (19%) <0.00001 
Rales >1/3 up lung fields, % (n) 166 (19%) 3 (14%) 0.58 108 (18%) 61 (20%) 0.43 159 (20%) 10 (12%) 0.1 
Jugular venous pressure, % (n) 387 (31%) 5 (16%) 0.07 256 (30%) 136 (31%) 0.8 365 (32%) 27 (16%) 0.00001 
Hepatomegaly, % (n) 240 (14%) 4 (10%) 0.44 166 (14%) 78 (13%) 0.75 224 (14%) 20 (9%) 0.02 
Hypertension, % (n) 1052 (60%) 28 (67%) 0.37 713 (59%) 367 (62%) 0.21 940 (60%) 140 (61%) 0.69 
Atrial fibrillation, % (n) 763 (43%) 10 (24%) 0.01 517 (43%) 256 (43%) 0.84 716 (46%) 57 (25%) <0.00001 
Myocardial infarction, % (n) 668 (38%) 11 (26%) 0.12 415 (34%) 264 (45%) 0.00002 595 (38%) 84 (37%) 0.74 
PCI, % (n) 385 (22%) 6 (14%) 0.24 248 (20%) 143 (24%) 0.08 345 (22%) 46 (20%) 0.53 
CABG, % (n) 282 (16%) 8 (19%) 0.6 180 (15%) 110 (19%) 0.04 254 (16%) 36 (16%) 0.87 
None 1326 (74%) 33 (2%) 0.31 927 (51%) 432 (24%) 0.39 1177 (65%) 182 (10%) 0.37 
Pacemaker only 116 (6%) 1 (0%)   70 (4%) 47 (3%)   105 (6%) 12 (1%)   
ICD only 151 (8%) 1 (0%)   101 (6%) 51 (3%)   133 (7%) 19 (1%)   
CRT only 34 (2%) 1 (0%)   25 (1%) 10 (1%)   34 (2%) 1 (0%)   
ICD and CRT 127 (7%) 6 (0%)   83 (5%) 50 (3%)   118 (7%) 15 (1%)   
Other 6 (0%) 0 (0%)   4 (0%) 2 (0%)   6 (0%) 0 (0%)   
Diabetes mellitus, % (n) 560 (32%) 11 (26%) 0.44 367 (30%) 204 (34%) 0.08 506 (32%) 65 (28%) 0.25 
COPD, % (n) 287 (16%) 3 (7%) 0.11 194 (16%) 96 (16%) 0.92 259 (16%) 31 (14%) 0.26 
Stroke, % (n) 162 (9%) 0 (0%) 0.04 101 (8%) 61 (10%) 0.17 148 (9%) 14 (6%) 0.1 
Peripheral artery disease, % (n) 185 (11%) 3 (7%) 0.48 120 (10%) 68 (11%) 0.31 173 (11%) 15 (7%) 0.04 
Aldosterone antagonists, % (n) 966 (55%) 20 (48%) 0.35 692 (57%) 294 (50%) 0.003 854 (54%) 132 (58%) 0.34 
Loop diuretics, % (n) 1752 (100%) 42 (100%) 0.66 1203 (99%) 591 (100%) 0.22 1567 (100%) 227 (99%) 0.3 
Digoxin, % (n) 321 (18%) 3 (7%) 0.06 231 (19%) 93 (16%) 0.08 296 (19%) 28 (12%) 0.02 
Haemoglobin, g/dL: mean (SD) 12.36 (1.85) 13 (1) 0.004 12.79 (1.73) 12 (2) <0.00001 12.4 (1.87) 12.23 (1.68) 0.17 
Creatinine, mmol/L: median (IQR) 486 (461-510) 
488 (461-
508) 0.55 482 (476-502) 500 (476-527) <0.00001 489 (451-514) 472 (451-491) <0.00001 
BUN, mmol/L: median (IQR) 28 (26.9-33.6) 33 (27-36) 0.002 27.4 (24.4-32.8) 29 (24-35) 0.0001 28.4 (21.5-34) 25.2 (21.5-30.5) <0.00001 
GFR MDRD formula, mL/min.1.73m2: mean (SD) 66 (23) 70 (25) 0.29 70 (22) 56 (23) <0.00001 64 (23) 78.16 (21.68) <0.00001 
Sodium, mmol/L: mean (SD) 138.28 (3.75) 
138.95 
(3.88) 0.27 138.42 (3.64) 138.03 (3.97) 0.04 138.11 (3.84) 139.58 (2.79) <0.00001 
Potassium, mmol/L: mean (SD) 3.27 (0.55) 3.29 (0.53) 0.86 3.26 (0.53) 3.31 (0.58) 0.08 3.27 (0.55) 3.33 (0.52) 0.1 
BNP, pg/mL: median (IQR) 3985 (2090-4357) 
3124 (2090-
3823) 0.04 3914 (3744-4282) 
4182 (3744-
4457) 0.008 3999 (2631-4394) 
3403 (2631-
3877) 0.004 
 
